Depemokimab Asthma Imaging and Bronchoscopy Sub-Study (NCT06979323)
The IMAGINE Study: A Phase 3b Open Label, Single Arm Study to Assess the Effect of Depemokimab on Airway Structure and Function in Asthma With Type 2 Inflammation Characterized by an Eosinophilic Phenotype Utilizing Quantitative High-resolution CT and Bronchoscopic Airway Sampling in a Sub Study
🩺 Plain-English Summary (8th-Grade Level)
Asthma is a chronic condition marked by narrowed and swollen airways due to inflammation leading to recurring symptoms that can vary and worsen unpredictably.\\xa0The purpose of this study is to assess how depemokimab, a monoclonal antibody, affects the structure and function of the lungs in asthmatic participants with type 2 inflammation, characterized by an eosinophilic phenotype.
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — Brooksville, Florida
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (50 Sites)
Showing the first 25 of 50 sites.
- GSK Investigational Site — Brooksville, Florida
- GSK Investigational Site — Plantation, Florida
- GSK Investigational Site — Kansas City, Kansas
- GSK Investigational Site — St Louis, Missouri
- GSK Investigational Site — New Brunswick, New Jersey
- GSK Investigational Site — New York, New York
- GSK Investigational Site — DuBois, Pennsylvania
- GSK Investigational Site — Philadelphia, Pennsylvania
- GSK Investigational Site — McKinney, Texas
- GSK Investigational Site — Mechelen,
- GSK Investigational Site — Namur,
- GSK Investigational Site — Ajax, Ontario
- GSK Investigational Site — Hamilton, Ontario
- GSK Investigational Site — London, Ontario
- GSK Investigational Site — Guangzhou,
- GSK Investigational Site — Shanghai,
- GSK Investigational Site — Tianjin,
- GSK Investigational Site — Brest,
- GSK Investigational Site — Créteil,
- GSK Investigational Site — La Tronche,
- GSK Investigational Site — Pessac,
- GSK Investigational Site — Reims,
- GSK Investigational Site — Bonn,
- GSK Investigational Site — Frankfurt,
- GSK Investigational Site — Athens,
📞 Contact the Study Coordinator
Phone: (877) 379-3718
Email: GSKClinicalSupportHD@gsk.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Asthma
- Investigating Dupilumab's Effect in Asthma by Genotype — Boston, Massachusetts
- Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma — Bakersfield, California
- Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma — Saraland, Alabama
- Reduce IDentified UNcontrolled Asthma — San Diego, California
- A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma — Little Rock, Arkansas
- REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study — La Jolla, California
Explore by condition: All Asthma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.